Antitumor activities of cytotoxic T and NK cells could be partially normalized by administration of immune checkpoint inhibitors (ICIs) such as antibodies against especially PD-1 or CTLA-4, which have produced unprecedent progression-free and even tumor-free survival in many cancer patients. This evidence concerns the gene PDCD1 and cancer.